8-K: bioAffinity to Host CyPath Lung Physician Roundtable

bioAffinity Technologies announced it will host a virtual physician roundtable to discuss the clinical integration and utility of its noninvasive CyPath Lung diagnostic test for early lung cancer detection.

Summary

• bioAffinity Technologies, Inc. will host a live virtual physician roundtable on April 8, 2026, at 7 p.m. ET/6 p.m. CT.
• The roundtable, titled "CyPath Lung in Practice: A Physician Roundtable Discussion," will feature leading pulmonologists.
• Discussions will focus on integrating CyPath Lung into clinical practice for lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors.
• Physicians will share real-world case studies demonstrating CyPath Lung's utility in guiding clinical decision-making, including identifying Stage 1A lung cancer and preventing unnecessary invasive procedures.
• CyPath Lung is a noninvasive test for early lung cancer detection in high-risk patients, utilizing flow cytometry and proprietary artificial intelligence (AI).
• Clinical study results showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules (less than 20 millimeters).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive announcement, as it indicates proactive efforts to drive adoption and educate the medical community about CyPath Lung's clinical utility, which is crucial for commercial success.

Positives

• Hosting a physician roundtable can increase awareness and adoption of CyPath Lung among healthcare professionals.
• The webinar will showcase real-world case studies demonstrating CyPath Lung's clinical utility, including early cancer detection (Stage 1A) and avoiding unnecessary invasive procedures.
• CyPath Lung offers high sensitivity (92%), specificity (87%), and accuracy (88%) for early lung cancer detection in high-risk patients with small indeterminate lung nodules.
• The noninvasive nature of CyPath Lung provides a less risky and potentially more cost-effective diagnostic option.

Risks

• The Company's ability to successfully commercialize CyPath Lung.
• The adoption of CyPath Lung by physicians and healthcare providers.
• The Company's ability to obtain and maintain regulatory approvals.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.

Future Outlook

The company aims for successful commercialization and adoption of CyPath Lung by physicians and healthcare providers, subject to obtaining and maintaining regulatory approvals. The webinar series is part of this strategy to drive adoption.

Management Comments

• "Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath Lung diagnostic test."
• "First of CyPath Lung in Practice webinar series focuses on need for greater certainty when diagnosing indeterminate pulmonary nodules."
• Gordon H. Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies, will moderate the discussion.

Industry Context

StockSavvy.ai notes that the diagnostic industry, particularly in oncology, is increasingly focused on noninvasive methods and early detection to improve patient outcomes and reduce healthcare costs. This webinar positions CyPath Lung within this trend, aiming to educate and gain adoption among pulmonologists, a critical step for new diagnostic technologies. The use of AI and flow cytometry aligns with advanced diagnostic approaches.

Stakeholder Impact

• Shareholders: Potential positive impact if the webinar series leads to increased adoption and commercial success of CyPath Lung, driving revenue growth.
• Healthcare Providers (Pulmonologists): Provides practical insights and education on integrating CyPath Lung into their practice, potentially improving patient care.
• Patients at High Risk for Lung Cancer: Offers a noninvasive diagnostic option for early detection, potentially leading to earlier treatment and better outcomes, and avoiding unnecessary invasive procedures.

Next Steps

• Hosting the "CyPath Lung in Practice: A Physician Roundtable Discussion" webinar on April 8, 2026.
• Continuing the "CyPath Lung in Practice" webinar series.
• Healthcare professionals are encouraged to register for the webinar.
• The webinar will be recorded and posted on the CyPath Lung website.

Key Dates

Recommendation

While the announcement of a physician roundtable to promote CyPath Lung is a positive step for commercialization and awareness, it is an event announcement rather than a report on financial performance or a major strategic shift. The company is actively working to drive adoption of its product, which is a good sign, but the impact on future revenue and profitability remains to be seen. Investors should hold to observe the effectiveness of these marketing efforts and subsequent financial reporting.

Keywords

CyPath Lung, lung cancer detection, noninvasive diagnostic, biotechnology, pulmonary nodule management, early cancer detection, bioAffinity Technologies, AI diagnostics, flow cytometry, healthcare webinar